A New American Heart Association CPR Certification School Has Just Opened in Brentwood, CA. This School Offers Daily Classes to the Public in CPR, BLS, ACLS, PALS, and CPR and First Aid.

BRENTWOOD, Calif., August 15, 2023 (Newswire.com) - Safety Training Seminars, an official American Heart Association© (AHA) Training Center in California, is proud to announce the opening of their newest CPR training center at 380 Carrol Court, Suite G, Brentwood, CA 94513. The new CPR training center is centrally located near Antioch and Discovery Bay, making it easily accessible to healthcare professionals in Contra Costa County. The office is open every day of the week and courses are offered to the public during regular business hours. 

Safety Training Seminars' new Brentwood CPR Training School offers a comprehensive range of courses for medical professionals, including CPR, BLS, ACLS, and PALS. Each course provides an innovative blend of online learning resources and on-site skills testing, ensuring that participants are fully prepared to handle life-threatening emergencies. After the training, students will immediately receive the official American Heart Association certification card. 

ACLS Courses offer initial and renewal certification in American Heart Association Advanced Cardiovascular Life Support, providing participants with the skills and knowledge needed to respond to cardiopulmonary arrest or other cardiovascular emergencies. 

CPR & First Aid Classes are designed for a wide variety of participants, such as teachers, babysitters, childcare care providers (EMSA), supervisors, and more. Students will learn the proper techniques for administering CPR to infants, children, and adults, as well as how to use AEDs, treat bleeding, respond to seizures, and more. After completing the course, all students will receive the official American Heart Association CPR and First Aid certification. 

BLS CPR courses provide new and renewal certification, helping attendees identify and respond to life-threatening emergencies. After attending this course, students will receive the official American Heart Association BLS certification card, which is valid for two years. 

PALS Courses are designed to meet the criteria for initial or renewal certification and teach participants how to recognize and respond to emergencies in infants and children. PALS stands for Pediatric Advanced Life Support. 

Safety Training Seminars has been providing crucial courses for certification and lifesaving training since 1989. The woman-owned company has 45 locations across Northern California, and they offer the most affordable, flexible training, with the latest resources and equipment. With their new Brentwood CPR office, Safety Training Seminars is committed to equipping Contra Costa residents with the skills and confidence to react quickly in emergency situations. To learn more about CPR and First Aid training in Brentwood, Antioch, and other locations across California, visit www.bayareacpr.org.

Contact Information:
Danielle Bell
General Manager
[email protected]
415-437-1600


Original Source: Safety Training Seminars Opens a New American Heart Association CPR Training Center in Brentwood, CA

TORONTO, August 15, 2023 (Newswire.com) - StageZero Life Sciences ("StageZero" or the "Company") (TSX: SZLS), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its second quarter financial results for the three and six months ended June 30, 2023, and will provide an update on its business operations.

For the quarter ended June 30, 2023 the Company generated revenue of $0.793 million. This is a small increase over Q1 2023 but continues the trajectory established post-COVID of Quarterly gains. Net loss narrowed to ($0.401) with a ($0.00) basic and diluted loss per common share.

"This has been a quarter of negotiating and concluding key partnerships that we expect to contribute strongly to our growth during the second half of this year," said James Howard-Tripp, Chairman & CEO of StageZero Life Sciences. "A major focus is on self-funded employers where we believe Aristotle and AVRT uniquely position us, the insurance groups that back them, but also to position ourselves for new, exciting initiatives in Preventative Health. Our partners reflect this," he added.

Strategic partnerships with laboratory groups and clinical groups will increase the number of employers, clinics and individual patients who can readily access StageZero's Aristotle test and AVRT/TREAT programs. Individuals and Employers are increasingly looking for better health outcomes and early detection notably contributes to a better outcome. In addition, it contributes to lower costs which, for Employers, is a driving metric for their bottom line.

Operational Update: will be provided during Analyst Call.

Q2 2023 Financial Results

All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.

The Company generated $1.6 million in cancer testing and treatment revenue for the six months ended June 30, 2023 as compared to COVID testing-related $2.3 million in revenue for the six months ended June 30, 2022 and realized a net loss of $2.2 million, or $0.02 basic and diluted loss per common share as compared to a $1.9 million net loss for the six months ended June 30, 2022, or $0.02 basic and diluted loss per common share.

The Company generated $0.793 million in cancer testing and treatment revenue for the three- months ended June 30, 2023, compared to COVID testing-related revenue of $0.998 million for the three months ended June 30, 2022. Net loss was $0.4 million, or $0.00 loss per fully diluted common share in Q2, 2023 as compared to a $1.3 million net loss, or $0.01 loss per fully diluted common share in Q2, 2022.

The Company's financial statements and management's discussion and analysis are available on www.sedar.com.

Analyst and Investor Call
Event Date: Tuesday August 15, 2023
Time: 8:30 am ET
Webcast Link: https://www.gowebcasting.com/12674
Conference Call Numbers
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340

About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a company innovating on the forefront of screening for the early detection of cancer. StageZero combines its proprietary liquid biopsy multi-cancer detection test, Aristotle®, with Physician led clinical programs; offering patients a unique treatment combination not found anywhere else.

Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types. Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use.

The COC Protocol program is managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. CareOncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease.

Aristotle® is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Contact Information:
Rebecca Greco
Investor Relations
[email protected]
1.855.420.7140 ext. 1838


Original Source: StageZero Life Sciences, Ltd Announces Q2 2023 Financial Results and Operational Update

Verified user reviews place ChiroFusion among the Top Chiropractic EHR platforms on Capterra.

BOCA RATON, Fla., August 15, 2023 (Newswire.com) - ChiroFusion announced today that Capterra, the world's leading software discovery and reviews platform, has recognized ChiroFusion as the Best Ease of Use Chiropractic EHR software platform. Ease of use is a fundamental concept that describes how easily users can utilize a product. The engineering team at ChiroFusion continues to dedicate significant time and resources to optimize ease of use while maximizing functionality. This ongoing investment has established ChiroFusion as one of the most user-friendly practice management platforms to learn and use.

"We deeply value our engaged and vocal user community that openly shares their experiences," said Damon Cozamanis D.C., President of ChiroFusion. "User reviews offer valuable insights to potential buyers of our chiropractic practice management solution, and their constructive feedback drives our innovation. This recognition from Capterra is particularly meaningful as it is based on genuine user ratings. There is no better measure of success."

Within Capterra, a repository of over 300,000 verified user reviews spanning 400+ software categories exists. The "Best" badges distill these reviews to honor the top-rated products within each category, assisting users in evaluating software options and facilitating well-informed purchasing decisions. ChiroFusion was also named a Top Performer in the 2022 Chiropractic Software Shortlist by Capterra. 

With over 560 reviewers giving ChiroFusion an average rating of 4.7 out of 5 stars, the following comments about ChiroFusion were shared:

• "The system is easy to learn, set up, and use. The SOAP notes are very quick to complete. The scheduler is fast and intuitive. I wish we had switched to ChiroFusion years ago!" - Alana B., Office Manager
• "Onboarding new patients is extremely simple for us using the digital intake forms and demographic prompts." - Eliza S., Front Desk Staff
• "We've found ChiroFusion easy to learn and use. Support is readily available whenever we have a question." - Katsia R., Chiropractic Billing Specialist

Discover more user reviews about ChiroFusion Chiropractic Software on Capterra's platform.

About ChiroFusion

ChiroFusion has developed an acclaimed practice management software that empowers chiropractors to optimize office efficiency and financial performance. Known for its intuitive and clear interface, ChiroFusion offers an unmatched array of features, including online patient scheduling and payment, appointment reminders, digital intake forms, compliant SOAP notes, and comprehensive billing and revenue management - all seamlessly integrated within a single web-based software solution. 

In 2016, ChiroFusion was named to the Inc 500 list of fastest-growing private companies in America, achieving 1,545% growth over a three-year period. For more information about ChiroFusion, visit www.chirofusionsoftware.com.

Contact Information:
Damon Cozamanis, D.C.
President / CEO
[email protected]
(877) 210-3230


Original Source: ChiroFusion Recognized as Best Ease of Use Chiropractic EHR Software by Capterra

MHT Spearheads Innovation through EHR Company Partnership

AURORA, Ill., August 15, 2023 (Newswire.com) - Mental Health Technologies (MHT) is excited to announce its partnership with leading healthcare solutions provider Meditab Software and its all-inclusive EHR system, Intelligent Medical Software (IMS).

MHT is an award-winning SaaS company that provides automated behavioral health assessments directly to patients on behalf of their healthcare provider. MHT's intuitive software sends assessments directly to the patient's email or phone, convenient for the patient and a time-saving measure for the physician.

A commanding software on its own, MHT increases its dominance by partnering with Meditab's Intelligent Medical Software (IMS), one of the country's most respected EHR systems. Meditab services over 41,000 healthcare professionals, 1,600 clinics, and 40 specialties.

This collaboration brings advanced resources to medical professionals by streamlining patient assessments with a sophisticated EHR, practice management, billing, and all-encompassing office management program into one intelligent and seamless system. Combining these industry-leading software systems automates time-consuming workflows, removing manual administrative intervention.

Dr. Peyman Palavan, Medical Director at Broadway Medical Center and client of both parties, says, "The facilitation of these companies brings a cutting-edge technology to the medical field. Their integration is going to provide a lot of relief to busy medical practices and create a synergy like we've never seen." He adds, "I'm excited to be a part of this partnership and have already seen how much our office and patient experience has improved." 

A compelling aspect of this partnership is seeing MHT's patent-pending SmarTest in use. This technology uses progressive intellect alongside historical patient data to determine when and how an individual should be tested for various mental health conditions. SmarTest can base its decisions on patient information such as age, gender, or other demographics. Each clinic or provider group can define its own system of rules for how they want SmarTest to work.

The MHT and Meditab integration offers clinicians:

• Improved patient outcomes - MHT sends patients their assessments beforehand, allowing for more thoughtful and honest answers. This benefit guides clinicians to make a more accurate diagnosis and treatment plan.
• Automated referrals - MHT sends referrals for patients that need behavioral health assistance directly to their partner provider. This is predetermined based on criteria that the clinicians set up and requires no administrative intervention from the referring provider.
• Configured follow-ups - Through SmarTest's intelligent design, clinicians determine how they would like to follow up with subsequent testing based on test results or demographics. 
• Saved time - Results are automatically uploaded into IMS once the patient completes their screening with no manual work. 
• Increased revenue - This collaboration automates data collection on your behalf and incorporates billing within the same flawless system, creating an environment where the provider can focus on patient interaction to determine the best treatment protocol. 
• Feedback - MHT and Meditab provide clients with superb customer service and work to innovate the latest technology based on their needs. 

Contact Information:
Ernie Wallerstein
MHT CEO
[email protected]
630-240-0323

Isabella Shefali Yeleswarapu
Metitab - Manager/Vendor Management
510-201-0130 ext 538


Original Source: Mental Health Technologies Announces Alliance With Meditab Software

The company landed in the top 10 for Healthcare Services on Inc. Magazine's 2023 list following its remarkable growth and ongoing success in advancing sustainable value-based care.

HOBOKEN, N.J., August 15, 2023 (Newswire.com) - Vytalize Health, a leading risk-bearing provider enablement platform, announced its debut on the Inc. 5000 list of America's fastest-growing private companies. The annual list showcases some of the nation's most successful up-and-coming companies from every industry.  

With more than 3,000 physicians across 36 states now using its platform, Vytalize Health ranked No. 71 overall on the national list of honorees after witnessing a remarkable 100% year-over-year increase in its patient base. 

"Value-based care offers a tremendous opportunity to fix the systematic problems in our healthcare system, and our growing team of incredibly talented people is at the forefront," said Faris Ghawi, Co-Founder and CEO of Vytalize Health. "2023 has been a transformational year. We continue to build momentum and lead with heart as we make value-based care more accessible and sustainable for providers and their patients." 

In the past year, that momentum has led Vytalize Health's rapid expansion nationwide, including the acquisition of Independent Physician Association (IPA) of New York, one of the nation's largest IPAs. In addition, Vytalize Health announced a highly successful $100 million funding round.

Most recently, Vytalize Health announced the addition of two new notable board members - former UnitedHealth Group CEO Dave Wichmann and Press Ganey President Dr. Amy Compton Phillips - highlighting its capacity to attract seasoned and influential talent. This after being recognized as a top-ranking company on Inc. Magazine's 2023 Best Workplaces list last spring. 

Complete results of the Inc. 5000 list, including company profiles and an interactive database sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000. The top 5000 companies will be featured in the September issue of Inc. magazine. 

About Vytalize Health

Vytalize Health is a risk-bearing provider enablement platform addressing the healthcare industry's biggest challenges with its cutting-edge value-based care delivery system. Vytalize partners with more than 3,000 leading providers to improve the quality of care through evidence-based medicine and a patient experience rooted in kindness. By delivering the right data at the right time in the workflow to physicians and their staff, Vytalize makes its partners more efficient and effective, allowing them to focus on proactive, personalized medicine to improve the value of care and lower costs. Learn more at www.vytalizehealth.com.

Contact Information:
Matt Buder Shapiro
Chief Marketing Officer
[email protected]
+12163370461


Original Source: Vytalize Health Named No. 71 on Inc. 5000 List of America's Fastest-Growing Companies

Leveraging AI-based molecular profiling from a digitized biopsy image to enable physicians to gain immediate oncology intelligence.

NEWPORT BEACH, Calif., August 15, 2023 (Newswire.com) - Hoag, the largest community-based healthcare system in southern California, and Imagene, an emerging leader in the field of AI-based precision oncology, are pleased to announce their strategic collaboration aimed at transforming molecular diagnosis and advancing personalized cancer care. The transformative research brings together Hoag's commitment to delivering world-class, personalized, and accessible healthcare, with Imagene's expertise in rapid AI-based molecular profiling, paving the way for merging new technologies within the clinical workflows.

By harnessing the power of AI-based molecular profiling to research the impact on improving turnaround time and personalized treatments, Hoag furthers its healthcare innovation leadership for the purpose of improving the delivery of cancer patient care and outcomes. One of the primary goals of the collaboration is to leverage advanced technologies' seamless integration to increase health equity by making fast and accurate molecular profiling accessible to more patients. 

Dr. David R. Braxton, Chief of Molecular Pathology Services at Hoag Family Cancer Institute and Principal Investigator for the study, is optimistic and excited about the potential findings derived from AI-based digital biomarker detection in cancer patients. "Traditional molecular biomarker testing is expensive and can take weeks for patients to receive their results. Imagene's AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies," says Dr. Braxton. "I expect that this kind of technology can be deployed into every hospital in the U.S. and lead to better and earlier cancer care for patients no matter where they live," he adds.

The partnership aims to overcome the current complexities associated with cancer diagnosis and explore the advancements AI-based molecular profiling can offer. By combining Imagene's technology expertise with Hoag's access to community patients, advanced digital lab services, and clinical diagnostic footprint, this collaboration demonstrates real promise for the future of personalized cancer care and achieving the goals of precision medicine.

"We are excited to collaborate with Hoag, a leading community-based hospital that shares our vision of making molecular profiling accessible to all patients who need it," says Dean Bitan, Co-founder and CEO of Imagene. "By working together, we aim to prove the value of rapid molecular testing that empowers medical teams to navigate the patient journey and make informed decisions related to the complex clinical junctions in cancer care."

Dr. Michael Brandt-Zawadzki, Senior Physician Executive at Hoag, states that "Hoag is committed to enhance community access to highly novel, cutting-edge medical technologies, including Imagene's. Hoag's innovation hub serves as a clinical test bed to accelerate AI/software development from premise to practice, and to support FDA approval and commercialization of life-saving innovation for cancer care." 

With over 80% of cancer patients in the U.S. choosing to get treatment in community-based settings for more personalized and convenient care, the collaboration between Imagene and Hoag provides a real-world setting to demonstrate the impact of innovative technologies on advancing community-based cancer care. 

About Hoag:

Hoag is a nonprofit, regional healthcare delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 15 urgent care facilities, 10 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of healthcare services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women's health, and orthopedics through Hoag's affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest-ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet^® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org.

About Imagene:

Imagene is an emerging leader in AI-based precision oncology leveraging AI to profile, within minutes, a broad range of cancer biomarkers from a digitized biopsy image alone. Imagene empowers physicians with immediate oncology intelligence to ensure optimal treatment for all cancer patients. Our success derives from our cutting-edge technology and multidisciplinary team of data scientists, biologists, software engineers, and medical experts. With a commitment to scientific excellence and collaboration, Imagene is dedicated to advancing precision oncology and improving patient outcomes. For more information, visit imagene-ai.com 

Contact Information:
Avital Rabani
Head of Marketing
[email protected]


Original Source: Hoag Hospital and Imagene Partner to Empower Rapid Cancer Diagnosis for Personalized Cancer Care